ClinicalTrials.gg
CompletedNCT00535392Updated Aug 31, 2011Results posted

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

A Phase 2 interventional study of Levetiracetam in Epilepsy, sponsored by UCB Pharma. Completed at 25 sites in 6 countries. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2011-08-31.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
42nd of 60
33 · median 94
Started
2007
with 6 others
Phase 2
11 of 60
none open now
Registered
22nd of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 42nd largest by enrollment, is one of 7 that started in 2007, is one of 11 in phase 2, and was the 22nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the safety, tolerability, and pharmacokinetics, of this formulation in children aged 4 to 16 years.

Read the detailed description

The primary objective of this study was to evaluate the safety and tolerability of levetiracetam intravenous 15-minute infusion administered every 12 hours, either as adjunctive treatment or monotherapy in children (4 to 16 years old) with epilepsy (except status epilepticus), either after switching from the equivalent levetiracetam oral dose administration or as a new antiepileptic treatment.

The evaluation period was to be considered as one complete set of 4 Pharmacokinetic (PK) samples for a maximum of 4 days;

  • For children already taking levetiracetam oral tablets or oral solution prior to entering the study, the levetiracetam intravenous (LEV IV) dose will be equivalent (mg-for-mg) to their oral dose. The first intravenous (IV) infusion was to be administered 12 hours after the last oral dose of levetiracetam.
  • For children not taking levetiracetam oral tablets or oral solution prior to entering the study:

    • If weight \< 50 kg: dose of levetiracetam intravenous (LEV IV) dose will be calculated on the basis of their weight at 20 mg/kg/day (i.e. 10 mg/kg twice daily).
    • If weight ≥ 50 kg: dose of levetiracetam intravenous (LEV IV) will be 1000 mg/day (i.e. 500 mg twice daily).

However, when necessary for the safety of the subject or when the investigator deemed it appropriate the levetiracetam intravenous (LEV IV) dose could be modified after one day.

Subjects were hospitalized for the duration of the levetiracetam IV treatment.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Child
  • Levetiracetam
  • Keppra®
  • Infusion
  • Intravenous
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 4 and 16 years of age, inclusive
  • The subject suffers from epilepsy (except status epilepticus)
  • The subject is requiring levetiracetam IV treatment in place of oral therapy for a short period of time

Exclusion criteria

Exclusion Criteria:

  • The subject has difficult venous accessibility
  • History of status epilepticus during the 3 months prior to visit 1.
  • The subject is taking felbamate at visit 1 or has been taking it in the past.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Drug: Levetiracetam

Interventions

  • Intravenous 100 mg/mL, twice a day, maximum of 4 days Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose. Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily).

    Also known as: ucb L059, Keppra®

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days)

    Time frame: Treatment period (up to 4 days)

Secondary outcomes

  1. Number of Subjects Who Received High-dose Levetiracetam Intravenous (LEV IV) (More Than 40 mg/kg/Day) During the Treatment Period (up to 4 Days)

    Time frame: Treatment period (up to 4 days)

  2. Number of Consecutive Levetiracetam Intravenous (LEV IV) Doses Received

    Time frame: Treatment period (up to 4 days)

07

Results

Posted Feb 25, 2011

Participant flow

Subjects were recruited from sites in the United States, Belgium, Germany, France, Mexico, and Turkey. The study began in September 2007 and continued until February 2010, with the last subject's visit occurring in February of 2010.

Participant flow — Overall Study
MilestoneLevetiracetam
Started33
Completed33
Not completed0

Outcome measures

PrimaryNumber of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days)
Time frame:
Treatment period (up to 4 days)
Reported as:
Number · Subjects
Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days)
SubjectsLevetiracetam
Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days)21
SecondaryNumber of Subjects Who Received High-dose Levetiracetam Intravenous (LEV IV) (More Than 40 mg/kg/Day) During the Treatment Period (up to 4 Days)
Time frame:
Treatment period (up to 4 days)
Reported as:
Number · Subjects
Number of Subjects Who Received High-dose Levetiracetam Intravenous (LEV IV) (More Than 40 mg/kg/Day) During the Treatment Period (up to 4 Days)
SubjectsLevetiracetam
Number of Subjects Who Received High-dose Levetiracetam Intravenous (LEV IV) (More Than 40 mg/kg/Day) During the Treatment Period (up to 4 Days)10
SecondaryNumber of Consecutive Levetiracetam Intravenous (LEV IV) Doses Received
Time frame:
Treatment period (up to 4 days)
Reported as:
Mean · Consecutive doses
Number of Consecutive Levetiracetam Intravenous (LEV IV) Doses Received
Consecutive dosesLevetiracetam
Number of Consecutive Levetiracetam Intravenous (LEV IV) Doses Received3.73 ± 1.61

Adverse events

Collected over Up to 4 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—3/33 (9.1%)12/33 (36.4%)
Most frequent serious events
Most frequent serious events
EventLevetiracetam
VOMITINGGastrointestinal disorders1/33
PYREXIAGeneral disorders1/33
CONVULSIONNervous system disorders1/33
Most frequent other events
Most frequent other events
EventLevetiracetam
NAUSEAGastrointestinal disorders3/33
DRY MOUTHGastrointestinal disorders3/33
CONVULSIONNervous system disorders3/33
HYPOTENSIONVascular disorders3/33
VOMITINGGastrointestinal disorders2/33
PYREXIAGeneral disorders2/33
WEIGHT DECREASEDInvestigations2/33
SOMNOLENCENervous system disorders2/33

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levetiracetam
<=18 years33
Between 18 and 65 years0
>=65 years0
Age Continuous
Age Continuous(years)Levetiracetam
Mean9.71 ± 3.38
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female14
Male19
Region of Enrollment
Region of Enrollment(participants)Levetiracetam
France4
United States7
Mexico10
Belgium5
Turkey6
Germany1
08

Study locations

25 sites
  • La Jolla, California, United States
  • Boston, Massachusetts, United States
  • Chesterfield, Missouri, United States
  • Buffalo, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Fort Worth, Texas, United States
  • Richmond, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Brussels, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Amiens, France
  • Lille, France
  • Paris, France
  • Heidelberg, Germany
  • Kehl, Germany
  • Torreon, Coahuila, Mexico
  • Puebla, CP, Mexico
  • Aguascalientes, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Puebla, Mexico
  • Ankara, Turkey
  • Izmir, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2007
First posted
Sep 26, 2007
Start
Sep 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Feb 25, 2011
Last update
Aug 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00535392
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 26, 2007
Start date
Sep 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Feb 25, 2011
Last update
Aug 31, 2011

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion